



Rudolf Stadler

Contact

Rudolf Stadler

Publications (13)

Latzka J, Assaf C, Bagot M, Cozzio A, Dummer R, Guenova-Hötzenecker E, Gniadecki R, Hodak E, Jonak C, Klemke C, Knobler R, Morris S, Nicolay J, Ortiz-Romero P, Papadavid E, Pimpinelli N, Quaglino P, Ranki A, Scarisbrick J, Stadler R, Väkevä L, Vermeer M, Wehkamp U, Whittaker S, Willemze R, Trautinger F. EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome – Update 2023. *Eur J Cancer* 2023; 195:113343.

Quaglino P, Scarisbrick J, Rocuzzo G, Abeldano A, Battistella M, McCormack C, Cowan R, Cozzio A, Cury-Martins J, Enz P, Geskin L, Guenova-Hötzenecker E, Kim Y, Knobler R, Litvinov I, Miyagaki T, Molgo M, Nicolay J, Papadavid E, Pinter-Brown L, Pujol Vallverdu R, Querfeld C, Ortiz-Romero P, Stadler R, Vermeer M, Bagot M, Hodak E. Identifying unmet needs and challenges in the definition of a plaque in mycosis fungoides: An EORTC-CLTG/ISCL survey. *J Eur Acad Dermatol Venereol* 2023; 37:680-688.

Garbe C, Keim U, Amaral T, Berking C, Eigentler T, Flatz L, Gesierich A, Leiter U, Stadler R, Sunderkötter C, Tüting T, Utikal J, Wollina U, Zimmer L, Zouboulis C, Ascierto P, Eggermont A, Grob J, Hauschild A, Sekulovic L, Long G, Luke J, Michielin O, Peris K, Schadendorf D, Kirkwood J, Lorigan P, Central Malignant Melanoma Registry (CMMR). Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment. *J Clin Oncol* 2022; 40:3741-3749.

Dippel E, Assaf C, Becker J, von Bergwelt-Baildon M, Bernreiter S, Cozzio A, Eich H, Elsayad K, Follmann M, Grabbe S, Hillen U, Klapper W, Klemke C, Loquai C, Meiß F, Mitteldorf C, Wehkamp U, Nashan D, Nicolay J, Oschlies I, Schlaak M, Stranzenbach R, Moritz R, Stoll C, Vag T, Weichenthal M, Wobser M, Stadler R. S2k-Guidelines – Cutaneous lymphomas (ICD10 C82 – C86): Update 2021. *J Dtsch Dermatol Ges* 2022; 20:537-554.

Dippel E, Assaf C, Becker J, von Bergwelt-Baildon M, Bernreiter S, Cozzio A, Eich H, Elsayad K, Follmann M, Grabbe S, Hillen U, Klapper W, Klemke C, Loquai C, Meiß F, Mitteldorf C, Wehkamp U, Nashan D, Nicolay J, Oschlies I, Schlaak M, Stranzenbach R, Moritz R, Stoll C, Vag T, Weichenthal M, Wobser M, Stadler R. S2k-Leitlinie – Kutane Lymphome (ICD10 C82-C86): Update 2021. *J Dtsch Dermatol Ges* 2022; 20:537-555.

Brüggen M, Schlaak M, Nguyen V, Romani N, Cozzio A, Nair G, Dimitriou F, French L, Dummer R, Guenova E, Wehkamp U, Nicolay J, Valencak J, Stranzenbach R, Li N, Stadler R, Jonak C, Bauer W, Porkert S, Blaschke A, Meiß F, working group for cutaneous lymphoma of the Arbeitsgemeinschaft Dermatologische Forschung (ADF). Clinical diversity and treatment approaches to blastic plasmacytoid dendritic cell neoplasm: a retrospective multicentre study. *J Eur Acad Dermatol Venereol* 2020

Dippel E, Meiß F, Mestel D, Nashan D, Nicolay J, Oschlies I, Schlaak M, Stoll C, Vag T, Weichenthal M, Wobser M, Loquai C, Lamos C, Klemke C, Assaf C, Becker J, von Bergwelt-Baildon M, Beyer M, Cozzio A, Eich H, Follmann M, Grabbe S, Hillen U, Klapper W, Stadler R. S2k-Leitlinie – Kutane Lymphome Update 2016 – Teil 2: Therapie und Nachsorge (ICD10 C82 – C86). *J Dtsch Dermatol Ges* 2018; 16:112-123.

Dippel E, Meiß F, Mestel D, Nashan D, Nicolay J, Oschlies I, Schlaak M, Stoll C, Vag T, Weichenthal M, Wobser M, Loquai C, Lamos C, Klemke C, Assaf C, Becker J, von Bergwelt-Baildon M, Beyer M, Cozzio A, Eich H, Follmann M, Grabbe S, Hillen U, Klapper W, Stadler R. S2k Guidelines – Cutaneous Lymphomas Update 2016 – Part 2: Treatment and Follow-up (ICD10 C82 – C86). *J Dtsch Dermatol Ges* 2017

Dippel E, Meiß F, Mestel D, Nashan D, Nicolay J, Oschlies I, Schlaak M, Stoll C, Vag T, Weichenthal M, Wobser M, Loquai C, Lamos C, Klemke C, Assaf C, Becker J, von Bergwelt-Baildon M, Beyer M, Cozzio A, Eich H, Follmann M, Grabbe S, Hillen U, Klapper W, Stadler R. S2k-Leitlinie – Kutane Lymphome Update 2016 – Teil 1: Klassifikation und Diagnostik (ICD10 C82 – C86). *J Dtsch Dermatol Ges* 2017; 15:1266-1273.

Dippel E, Meiß F, Mestel D, Nashan D, Nicolay J, Oschlies I, Schlaak M, Stoll C, Vag T, Weichenthal M, Wobser M, Loquai C, Lamos C, Klemke C, Assaf C, Becker J, von Bergwelt-Baildon M, Beyer M, Cozzio A, Eich H, Follmann M, Grabbe S, Hillen U, Klapper W, Stadler R. S2k Guidelines – Cutaneous Lymphomas Update 2016 – Part 1: Classification and Diagnosis (ICD10 C82 – C86). *J Dtsch Dermatol Ges* 2017; 15:1266–1273.

Trautinger F, Quaglino P, Ranki A, Scarisbrick J, Stadler R, Väkevä L, Vermeer M, Whittaker S, Willemze R, Pimpinelli N, Papadavid E, Eder J, Assaf C, Bagot M, Cozzio A, Dummer R, Gniadecki R, Klemke C, Ortiz-Romero P, Knobler R. European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome – Update 2017. *Eur J Cancer* 2017; 77:57–74.

Assaf C, Becker J, Beyer M, Cozzio A, Dippel E, Klemke C, Kurschat P, Weichenthal M, Stadler R. Treatment of advanced cutaneous T-cell lymphomas with non-pegylated liposomal doxorubicin--consensus of the lymphoma group of the Working Group Dermatologic Oncology. *J Dtsch Dermatol Ges* 2013; 11:338–47.

Dummer R, Bernengo M, Cozzio A, Bagot M, Stadler R, Weichenthal M, Morris S, Whittaker S, Karrasch M, Hasan B, Becker J, Quaglino P, Knobler R. Prospective international multicenter phase II trial of intravenous pegylated liposomal doxorubicin monochemotherapy in patients with stage IIB, IVA, or IVB advanced mycosis fungoides: final results from EORTC 21012. *J Clin Oncol* 2012; 30:4091–7.

Projects (0)

No results found.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch